A5079916769- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Radiation Dose and Imaging
- Advanced X-ray and CT Imaging
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer Cells and Metastasis
- COVID-19 and healthcare impacts
- Ultrasound in Clinical Applications
- Urinary and Genital Oncology Studies
- Vascular Procedures and Complications
- Radiology practices and education
- Liver Diseases and Immunity
- Hip disorders and treatments
- Vascular Tumors and Angiosarcomas
- CNS Lymphoma Diagnosis and Treatment
- Atomic and Subatomic Physics Research
- Liver Disease and Transplantation
- Bladder and Urothelial Cancer Treatments
Memorial Sloan Kettering Cancer Center
2016-2023
Kettering University
2021
Grant Medical Center
2018
University of Cagliari
2018
Cornell University
2017
American University of Beirut Medical Center
2015
American University of Beirut
2015
Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity the periphery may also be an important contributor response. A detailed assessment response dynamics individual metastasis could provide insight systemic and local features that mediate resistance immunotherapy.Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair deficiency...
We describe the clinical and genomic landscape of non-small cell lung cancer (NSCLC) cohort American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). A total 1,846 patients with NSCLC whose tumors were sequenced from 2014 to 2018 at four institutions participating in AACR GENIE randomly chosen curation using PRISSMM data model. Progression-free survival (PFS) overall (OS) estimated treated standard...
Clinical patterns and the associated optimal management of acquired resistance to PD-(L)1 blockade are poorly understood.All cases metastatic lung cancer treated with at Memorial Sloan Kettering were reviewed. In (complete/partial response per RECIST, followed by progression), clinical distinguished as oligo (OligoAR ≤ 3 lesions disease progression) or systemic (sAR). We analyzed relationships between patient characteristics, burden/location disease, outcomes, efficacy therapeutic...
Patients with non-small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate outcomes first-line pembrolizumab in patients advanced NSCLC, PD-L1 Tumor Proportion Score (TPS) of ≥50%, an ECOG PS 2.We performed multicenter retrospective analysis metastatic NSCLC TPS ≥50% (negative for genomic alterations EGFR ALK) who received treatment pembrolizumab. Clinical...
Oncologic patients who develop chemotherapy-associated liver injury (CALI) secondary to chemotherapy treatment tend have worse outcomes. Biopsy remains the gold standard for diagnosis of hepatic steatosis. The purpose this article is compare 2 alternatives: Proton-Density-Fat-Fraction (PDFF) MRI and MultiMaterial-Decomposition (MMD) DECT.49 consecutive oncologic treated with Chemotherapy underwent abdominal DECT within weeks each other. Two radiologists tracked Regions Interest independently...
The aim of this study was to investigate the value pharmacokinetic modeling for quantifying 11C-choline uptake in patients with recurrent prostate cancer. Methods: In total, 194 clinically suspected recurrence cancer underwent dynamic PET over pelvic region (0-8 min), followed by a 6-min static acquisition at about 25 min after injection. Regions interest were drawn sites disease identified radiologist experience nuclear medicine. and pharmacokinetics evaluated SUV, graphical analysis...
Abstract Determining which lung cancer patients are likely to respond immune checkpoint inhibitors (ICI) remains a crucial challenge. Existing FDA-approved biomarkers lack sensitivity and specificity for identifying treatment candidates. To overcome this problem, we present computational biomarker predicting ICI response directly from routine H&E stained whole slide images of the initial biopsy. achieve this, developed an end-to-end deep learning system (EPL-GNN) that performs...
To identify discrepancies in fludeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) reports generated by general radiologists and subspecialized oncological for patients with diffuse large B-cell lymphoma (DLBCL), to assess if such impact patient management.Two retrospectively reviewed 72 PET/CT scans of DLBCL referred our institutions between 2009 2011, recorded the outside second-opinion regarding multiple preset criteria using kappa statistic (Κ), including disease...
Abstract Rationale: Hepatic epithelioid hemangioendothelioma (EHE) is a rare malignant vascular tumor of endothelial origin with highly variable clinical presentation and natural history. Given its origin, new therapies inhibitors growth factor (VEGF) have been introduced in the treatment these patients shown promising results. Few reports described role 18 F-Fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography ( F-FDG PET/CT) evaluation this after...
The mammalian target of rapamycin inhibitor everolimus is an established therapy for well-differentiated (WD) foregut neuroendocrine tumors (NETs). Pre-clinical data demonstrates a potential synergistic role cyclin dependent kinase 4/6 inhibition and to treat this disease. In phase II multicenter study, patients with advanced WDNETs received combination ribociclib until confirmed disease progression or unacceptable toxicity. first 12 300 mg three weeks in row 1 week break 2.5 daily...
To evaluate the accuracy of single-source dual-energy computed tomography (ssDECT) in iodine quantification using various segmentation methods an ex vivo model.Ten sausages, injected with variable quantities iodinated contrast, were inserted into 2 livers and scanned ssDECT. Material density images reconstructed. Three radiologists segmented each sausage. Iodine concentration, volume, absolute quantity measured. Agreement between measured was assessed concordance correlation coefficient...
9568 Background: Patients with non-small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group performance status (ECOG PS) have been excluded from immunotherapy clinical trials. We sought to evaluate outcomes first-line pembrolizumab in patients advanced NSCLC, PD-L1 tumor proportion score (TPS) of ≥50%, an ECOG PS 2. Methods: performed multicenter retrospective analysis metastatic NSCLC ≥50% (negative for genomic alterations EGFR ALK) who received treatment commercial...
<p>Supplemental Table 4</p>
<p>Supplemental Table 1</p>
<p>Supplemental Figure 3: PFS estimates for patients with NSCLC treated standard first- and second-line therapies.</p>
<p>Supplemental Table 2</p>
<p>Supplemental Figure 2: OS and PFS for patients with NSCLC treated first-line platinum-based chemotherapy.</p>
<p>Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.</p>